Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.76 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.63 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934922 | 0.89 | PTGER4 (0.61) | PTGER4PTGER2LIPGCYP3A4MAPK14 | |
| SCHEMBL7181929 | 0.88 | PTGER4 (0.84) | PTGER4PTGER2LIPGCYP3A4MAPK14 | |
| SCHEMBL13954494 | 0.87 | PTGER4 (0.60) | PTGER4PTGER2ALDH1A1L3MBTL1MAPK8 | |
| Hydrochloric Acid SCHEMBL6908368 | 0.86 | PTGER4 (0.77) | PTGER4PTGER2LIPGCYP3A4MAPK14 | |
| SCHEMBL4085505 | 0.86 | PTGER4 (0.77) | PTGER4PTGER2LIPGCYP3A4MAPK14 | |
| SCHEMBL4450937 | 0.86 | PTGER4 (1.00) | PTGER4PTGER2CYP3A4MAPK14MAPK8 | |
| SCHEMBL13954353 | 0.85 | PTGER4 (0.66) | PTGER4PTGER2LIPGMAPTTHRB | |
| SCHEMBL13954367 | 0.85 | PTGER4 (0.58) | PTGER4PTGER2ALDH1A1L3MBTL1MAPK8 | |
| SCHEMBL4450413 | 0.84 | PTGER4 (0.81) | PTGER4PTGER2LIPGCYP3A4MAPK14 | |
| SCHEMBL4087663 | 0.84 | PTGER4 (0.74) | PTGER4PTGER2LIPGL3MBTL1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | PTGER4 1/4885PTGER2 2/4885LIPG 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.